Illumina News and Research

RSS

Broad Institute purchases 30 additional Genome Analyzers from Illumina

Illumina, Inc. today announced that the Broad Institute has purchased 30 additional Genome Analyzers, increasing its total installed base of Illumina systems to 89.

From Illumina, Inc. 6 Nov 2009

Ambry Genetics awarded CSP status for Agilent's SureSelect Target Enrichment System

Agilent Technologies Inc. and Ambry Genetics today announced that Ambry is the first organization to achieve Certified Service Provider (CSP) status for Agilent's SureSelect Target Enrichment System for next-generation sequencing.

23 Oct 2009

CHOP implements InforSense-based Translational Research Solution to study complex genetic disease

IDBS, the leading worldwide provider of research data management and analytics solutions to R&D organizations, today announced that The Children's Hospital of Philadelphia (CHOP), one of the leading pediatric hospitals and research facilities in the world, has implemented the InforSense-based Translational Research Solution to advance the understanding of complex genetic disease.

22 Oct 2009

Illumina announces 2010 roadmap for Infinium whole-genome genotyping platform

At the 59th annual meeting of the American Society of Human Genetics, Illumina, Inc. today announced its 2010 roadmap for the Infinium whole-genome genotyping platform, offering products capable of analyzing up to five million (5M) variants per sample.

From Illumina, Inc. 22 Oct 2009

New workflow automation system from Illumina

At the 59th annual meeting of the American Society of Human Genetics, Illumina, Inc. announced the launch and immediate availability of cBot, a new standard for ease-of-use and sequencing workflow automation.

From Illumina, Inc. 21 Oct 2009

Illumina and Solexa deny patent infringement allegations

Illumina, Inc. today announced that, together with Solexa its wholly owned subsidiary, it has filed its initial response to the lawsuit brought by Life Technologies and Applied Biosystems on September 21, 2009 in U.S. District Court in Wilmington, Delaware. In their answer, Illumina and Solexa have denied all of Life’s and AB’s allegations of patent infringement, and have asserted that AB’s licensed patents are invalid.

From Illumina, Inc. 15 Oct 2009

BUSM researchers identify genes that influence the onset age of Parkinson's Disease

Researchers from Boston University School of Medicine (BUSM) have identified genes which may influence the onset age of Parkinson's Disease (PD). The findings, which currently appear on-line in BMC Medical Genetics, are the first to identify genes contributing to the variation in onset age and may help identify mechanisms and therapeutic targets capable of delaying symptoms.

8 Oct 2009

Illumina launches IlluminaCompute for its Genome Analyzer sequencing platform

At the BioIT World Europe Conference, Illumina, Inc. announced the launch of IlluminaCompute, a fully integrated computing solution for its Genome Analyzer sequencing platform.

From Illumina, Inc. 6 Oct 2009

OICR completes evaluation of NEB's new reagents for use with the Illumina Genome Analyzer

Dr. John McPherson, Platform Leader, Cancer Genomics and High-Throughput Screening, and Dr. Kamran Shazand, Project Manager, of the Ontario Institute for Cancer Research (OICR) led a team of scientists who have completed a thorough evaluation of the NEBNext(TM) DNA Sample Prep Reagents for use with OICR's Illumina® Genome Analyzer II.

From New England Biolabs 1 Oct 2009

Illumina to defend Genome Analyzer System patent infringement suit

Illumina, Inc. today announced that it has been served with a complaint filed on September 21, 2009 in the U.S. District Court in Wilmington, Delaware naming Illumina as a defendant. The complaint names as plaintiffs Life Technologies Corporation; Applied Biosystems LLC; a Russian research institute; two individuals listed as inventors on the asserted patents; and another individual who appears to have an ownership interest in the patents.

From Illumina, Inc. 28 Sep 2009

Agilent Technologies introduces SureSelect Human All Exon Kit

Agilent Technologies Inc. (NYSE:A) has chosen the Cambridge Health Institute’s Next-Generation Sequencing Analysis conference today to introduce its SureSelect Human All Exon Kit for target enrichment prior to next-generation DNA sequencing.

23 Sep 2009

NIH funding helps to boost sales of DNA sequencers

Rapid increase in output from second-generation DNA sequencers has enabled new levels of productivity and new experiments. This, along with funding from the stimulus bill, has caused rapid adoption of these machines, according to healthcare market research firm Kalorama Information, helping to fuel sales of DNA sequencers to $480 million in 2008. In its report "DNA Sequencing Equipment and Services Markets, 2nd Edition," Kalorama says more changes are on the way and will drives sales growth of 19% annually through 2013.

23 Sep 2009

Raindance Technologies and CLC to develop software for resequencing analysis

RainDance Technologies and CLC bio today announced a partnership to develop specialized software for the analysis of targeted resequencing data generated by workflows incorporating RainDance’s Sequence Enrichment Solution and next generation DNA sequencing platforms.

18 Sep 2009

Illumina delivers its first individual genome sequence to Dr. Hermann Hauser

Illumina, Inc. today announced that it has delivered Hermann Hauser’s genome sequence. Dr. Hauser, Partner, Amadeus Capital Partners Ltd, is the first consumer to purchase Illumina’s individual genome sequencing service working with his physician, Michael Nova, MD, of Pathway Genomics.

From Illumina, Inc. 31 Aug 2009

Illumina's new stock repurchase program effective in returning value to shareholders

Illumina, Inc. today announced that its Board of Directors has approved a new stock repurchase program, authorizing the Company to repurchase in the aggregate up to $75 million of its outstanding common stock.

From Illumina, Inc. 25 Aug 2009

Febit's DNA-capture method selected by NCGR to re-sequence 400 genes involved in childhood diseases

The National Center for Genome Resources (NCGR) has selected febit's DNA-capture method, HybSelect, to re-sequence the exons of genes involved in over 400 of the most devastating childhood diseases with the ultimate goal of developing genetic tests to detect carrier status for recessive genetic diseases in prospective parents.

11 Aug 2009

Expression Analysis launches new look

The url stays the same, but www.ExpressionAnalysis.com looks a lot different today. The redesigned website allows researchers and scientists to more easily navigate and locate the information and services they are looking for, in most cases in just one click. Additionally a revamped search tool enables users to find valuable information on a wide range of scientific topics.

6 Aug 2009

DNA alterations on human chromosome 9 linked to glioblastoma

Mayo Clinic researchers and colleagues at the University of California San Francisco (UCSF) have found a connection between DNA alterations on human chromosome 9 and aggressive brain cancer known as glioblastoma. The findings are reported in the current online issue of Nature Genetics.

5 Jul 2009

New technique for carrying out gene-expression profiling

A novel technique for carrying out gene-expression profiling is set to challenge the market dominance of the current, widely used methodology, reports Genetic Engineering & Biotechnology News (GEN).

6 Apr 2009

Alzheimer's disease neuroimaging initiative announces completion of genome-wide analysis

Researchers announced today that a high-density genome wide analysis of participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI; www.adni-info.org) is more than 95% complete and that data will be shared with scientists around the world for further analysis.

16 Mar 2009